MBI’s FS069 bid accepted in Europe

April 16, 1997

Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the

Molecular Biosystems of San Diego announced last month that the European Medicines Evaluation Agency (EMEA) has accepted MBI's marketing authorization application (MAA) for FS069, a second-generation ultrasound contrast agent. If EMEA approves the application, MBI and its marketing partner, Mallinckrodt of St. Louis, will be able to sell FS069 in all countries of the European Union.